![Christian Leisner](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Postes actifs de Christian Leisner
Sociétés | Poste | Début | Fin |
---|---|---|---|
CDR-Life Inc.
![]() CDR-Life Inc. BiotechnologyHealth Technology CDR-Life Inc. is a Swiss biotherapeutics company that develops novel immunotherapies to target the power of the immune system specifically to tumor cells. CDR-Life is based in Schlieren, Switzerland, and was founded in 2017 by Leonardo Borras, Christian Leisner, Dominik Escher, Rouven Bingel-Erlenmeyer, and Konstantin von Schulthess. The company's proprietary antibody platform targets intracellular tumor antigens presented on the major histocompatibility complex (MHC) with high affinity and specificity, which allows them to develop a pipeline of first-in-class therapeutics across a broad range of solid tumors. The company is backed by leading cross-Atlantic investors and has an existing collaboration and licensing agreement with Boehringer Ingelheim for a novel antibody fragment therapy to treat macular degeneration. Christian Leisner has been the CEO since 2017. | Directeur/Membre du Conseil | 01/01/2017 | - |
Directeur Général | 01/01/2017 | - | |
Fondateur | 01/01/2017 | - |
Historique de carrière de Christian Leisner
Anciens postes connus de Christian Leisner
Sociétés | Poste | Début | Fin |
---|---|---|---|
ESBATech, a Novartis Co. GmbH
![]() ESBATech, a Novartis Co. GmbH Miscellaneous Commercial ServicesCommercial Services ESBATech AG develops antibody fragment therapeutics. The firm's antibody fragment is derived from human antibody fragment scaffolds. It develops Immuna, an antigen-independent platform to screen, select, and optimize highly-stable and soluble, single-chain antibody fragments. The company was founded by Dominik Escher in September 1998 and is headquartered Schlieren, Switzerland. | Corporate Officer/Principal | - | - |
Statistiques
Internationale
Suisse | 3 |
Opérationnelle
Corporate Officer/Principal | 1 |
Director/Board Member | 1 |
Chief Executive Officer | 1 |
Sectorielle
Commercial Services | 2 |
Health Technology | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Entreprise privées | 2 |
---|---|
ESBATech, a Novartis Co. GmbH
![]() ESBATech, a Novartis Co. GmbH Miscellaneous Commercial ServicesCommercial Services ESBATech AG develops antibody fragment therapeutics. The firm's antibody fragment is derived from human antibody fragment scaffolds. It develops Immuna, an antigen-independent platform to screen, select, and optimize highly-stable and soluble, single-chain antibody fragments. The company was founded by Dominik Escher in September 1998 and is headquartered Schlieren, Switzerland. | Commercial Services |
CDR-Life Inc.
![]() CDR-Life Inc. BiotechnologyHealth Technology CDR-Life Inc. is a Swiss biotherapeutics company that develops novel immunotherapies to target the power of the immune system specifically to tumor cells. CDR-Life is based in Schlieren, Switzerland, and was founded in 2017 by Leonardo Borras, Christian Leisner, Dominik Escher, Rouven Bingel-Erlenmeyer, and Konstantin von Schulthess. The company's proprietary antibody platform targets intracellular tumor antigens presented on the major histocompatibility complex (MHC) with high affinity and specificity, which allows them to develop a pipeline of first-in-class therapeutics across a broad range of solid tumors. The company is backed by leading cross-Atlantic investors and has an existing collaboration and licensing agreement with Boehringer Ingelheim for a novel antibody fragment therapy to treat macular degeneration. Christian Leisner has been the CEO since 2017. | Health Technology |
- Bourse
- Insiders
- Christian Leisner
- Expérience